DOSAGE AND ADMINISTRATION Adults
The recommended dose for VIRAMUNE is one 200 mg tablet daily for the first 14
days, followed by one 200 mg tablet twice daily, in combination with other
antiretroviral agents. The lead-in period has been observed to decrease the
incidence of rash. For concomitantly administered antiretroviral therapy, the
manufacturer's recommended dosage and monitoring should be followed.
VIRAMUNE XR extended release tablets (400 mg once daily) is also available for
use after the lead-in period. Patients must never take more than one form of
nevirapine at the same time.
No adjustments required.
No specific guidelines available. Adjustment in dosage is unlikely.
An additional 200 mg dose is recommended following dialysis.
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read